Condition 1: aplastic anaemia. Condition 2: Multiple myeloma. Condition 3: Hodgkin lymphoma. Condition 4: non-Hodgkin lymphoma. Condition 5: Lymphoblastic leukemia. Condition 6: Myeloblastic leukemia. Other aplastic anaemias Multiple myeloma Hodgkin lymphoma Other and unspecified types of non-Hodgkin lymphoma Lymphoid leukaemia Myeloid leukaemia
Conditions
Interventions
Intervention 1: In the intervention group: In this intervention study, a continuous care model was used to educate patients undergoing stem cell transplantation. After collecting information at the fi
Sponsors
Vice chancellor for research of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 60 Years
Inclusion criteria
Inclusion criteria: Have at least reading and writing skills, Age between 15 and 60 years, Lack of verbal and perceptual and psychological disorders The patient should not be simultaneously in another study
Exclusion criteria
Exclusion criteria: The patient is a member of the treatment team, Incidence of intense complications after bone marrow transplantation Relapse of disease Death of Patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Graft-Versus-Host Disease (GVHD). Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: GVHD grading using the Glucksberg grade scale.;Oral mucositis. Timepoint: Before Stem Cell Transplantation and every 4 weeks for the first 3 months after transplantation. Method of measurement: WHO Oral Mucositis Grading Scale.;The rate of re-admission related to stem cell transplantation. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: the number of days that patient admit in the post-transplant stem cell care unit.;Signs and symptoms of infection. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Clinical examination and symptom registration.;Anxiety. Timepoint: Before Stem Cell Transplantation and every 4 weeks for the first 3 months after transplantation. Method of measurement: The State-Trait Anxiety Inventory and VAS Tool. | — |
Secondary
| Measure | Time frame |
|---|---|
| The main reason for re-admission. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Readmission Questionnaire.;Days of readmission. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Readmission Questionnaire.;Types of treatments performed on re-admission. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Readmission Questionnaire.;Skin graft-versus-host disease. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: GVHD grading using the Glucksberg grade scale.;Gastrointestinal graft-versus-host disease. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: GVHD grading using the Glucksberg grade scale.;Hepatic graft-versus-host disease. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: GVHD grading using the Glucksberg grade scale.;Fever. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Clinical examination and symptom registration.;Shivering. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Clinical examination and symptom registration.;Dysuria. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Clinical examination and symptom registration.;Airway secretions. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Clinical examination and symptom registration.;The cytomegalovirus (CMV) status. Timepoint: Every 4 weeks for the first 3 months after transplantation. Method of measurement: Using real time PCR (copies/mL). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Esmaielzadeh
Faculty of Nursing and Midwifery, Tehran University of Medical Sciences
Outcome results
None listed